ClinicalTrials.gg
RecruitingNCT07660029BUCSUpdated Jun 24, 2026

BloodTrackR Usability and Concordance Study (BUCS): Evaluating a Smart Home-Based Blood Collection Platform for Remote Monitoring in Rheumatoid Arthritis

An observational study in Rheumatoid Arthritis (RA) and Remote Patient Monitoring, sponsored by University of Ulster. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by University of Ulster · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 314 studies in Arthritis, Rheumatoid with a site in United Kingdom — 18 open to participants now, 40 under way, 3 of them phase 3. Arthritis, Rheumatoid · United Kingdom.

Planned enrollment
67th of 75
20 · median 151
Started
2026
with 2 others
Observational
75 of 314
8 open now
Primary completion
2026-09
later than 11 of 39 live
Registered
314th of 314
by date

Among the 314 studies in Arthritis, Rheumatoid with a site in United Kingdom, this one is the 67th largest by planned enrollment of the 75 observational ones that give a count, is one of 3 that started in 2026, is one of 75 observational ones, reaches primary completion later than 11 of the 39 other live ones, and was the 314th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

18 of the 314 studies in Arthritis, Rheumatoid with a site in United Kingdom are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 314 studies in Arthritis, Rheumatoid with a site in United Kingdom, or all of them as a file.
02

Study summary

The BloodTrackR Usability and Concordance Study (BUCS) is evaluating a novel home-based blood collection device and companion mobile application for people with rheumatoid arthritis. Participants will use the BloodTrackR device to collect a finger-prick blood sample at home and complete symptom assessments through the app.

The study will assess how easy the device and app are to use, whether participants can successfully collect high-quality blood samples outside of a healthcare setting, and how closely the results compare with standard venous blood samples collected by a phlebotomist. Findings will help determine the potential of BloodTrackR to support remote monitoring and reduce reliance on NHS phlebotomy services.

Read the detailed description

Background:

Blood testing is one of the most important tools in healthcare, but the way samples are collected and processed today creates barriers for both patients and the NHS. Most blood tests require a hospital or GP visit for venous blood draw. This can be inconvenient and stressful for patients, particularly those with long-term conditions who need frequent monitoring, and it places additional demand on already stretched NHS staff. In clinical trials, reliance on centralised sample collection and processing slows recruitment and increases costs. Current alternatives, such as dried blood spot (DBS) sampling, have limitations in accuracy due to the "haematocrit effect," which reduces trust in results.

The impact is significant: patients face delays and additional travel, NHS services struggle with capacity, and healthcare costs increase. There is an urgent need for simple, reliable solutions that support blood testing in the community, reduce workforce pressure, and improve patient experience.

BloodTrackR, is a novel blood collection device and companion mobile app developed by the researchers that allows people collect their own blood samples at home. A key focus of BloodTrackR is the measurement of inflammation in rheumatoid arthritis, which is not visible to clinicians outside clinic visits, so that treatment can be adjusted in real time rather than at the next scheduled appointment. This helps identify early signs of disease flares and ensures disease activity is kept under control. Given that chronic inflammatory conditions are frequently associated with multi-morbidity, BloodTrackR could also provide a platform for monitoring co-occurring conditions, such as diabetes or cardiovascular disease, from the same device. This creates opportunities to consolidate patient monitoring, reduce missed opportunities for treatment adjustment, and ensure therapy is as effective as possible across multiple conditions.

This reusable device incorporates a proprietary plasma separation process that produces dried plasma samples, rather than dried blood spots, overcoming limitations of the haematocrit effect. Built-in sample stabilisation, temperature monitoring, and precise time-stamping safeguard sample quality and integrity during transport and storage. The companion mobile app links samples with patient-reported symptoms and medications, creating rich longitudinal datasets that can inform clinical decision-making, support remote monitoring, and trigger earlier intervention.

This research will evaluate BloodTrackR, a novel blood collection device and companion App designed for use at home or in community settings and in addition, to ascertain:

  1. If the participants can reliably use BloodTrackR to collect and stabilise high-quality blood plasma samples outside of a hospital setting
  2. Will this approach reduce the burden on NHS services?

Aim: This study aims to evaluate the reliability, usability, and acceptability of BloodTrackR-a novel at-home blood/collection device and companion mobile app-to determine its capacity to reduce reliance on NHS phlebotomy services and identify measurable outcomes that indicate its potential to alleviate NHS workforce burden.

Objectives:

  • To Assess usability and patient acceptability of the device and app in real-world settings.
  • Evaluate the quality and stability of samples collected and transported from home.
  • Gather feedback from PPI workshops to inform device refinement and adoption.
  • Generate evidence to demonstrate potential workforce and system benefits for the NHS.

Study Design:

The current research is a usability mixed method study and will be conducted in 3 phases:

Methodology:

Recruitment:

Participants n=20 will be recruited via Rheumatoid Arthritis support groups and their charity partners via the group leaders for which our centre has extensive experience working with and who have already provided feedback on early device design. In addition, participants who have previously taken part in research studies under the CI and have provided enduring consent will also be sent information on the study.

The researcher employed onto the study will arrange to attend the group(s) to give an informal talk about the research and leave Participant information sheets (PIS) for those interested and to answer any questions. If after reading the PIS and the participant is happy to proceed, they will be asked to contact the researcher via the contact details provided on the PIS to check their eligibility via a screening questionnaire. If eligible, the researcher will then gain informed consent either by post or in person prior to participants being enrolled onto the study.

Phase 1: Usability and acceptability: Those participants who have consented to participate in the study will be advised that they will receive their BloodTrackR device by post in a pack complete with instructions. This will be supplemented by remote training on the correct use of the BloodTrackR device and companion app, delivered via Microsoft Teams, to support participants in collecting their own capillary blood sample at home and simultaneously log their assessment of disease activity via the Clinical Disease Activity Index (CDAI) and the Routine Assessment of Patient Index data 3 (RAPID 3) assessment questionnaires which measure the participants physical function, symptoms, pain, and overall global health all via the app. The logged data is accessible only to the named researcher(s) and is de-identified. Usability and compliance will be assessed via a structured questionnaire which will be posted out along with the device to complete when the participant has completed the procedure. In addition, the data usage logged by the App will be collected. This feedback will provide rich insight into user experience, barriers to adoption and opportunities for refinement.

Phase 2: Concordance Study Patient-collected capillary device samples collected via the BloodTrackR device will be validated against matched venous blood draws which will be collected around the same time as they self-collect their device based capillary sample. The participant will be asked to return the device with the sample contained in the well to the Personalised Medicine Centre;PMC in the addressed, prepaid envelope provided. The 6ml venous serum sample will be collected by a qualified phlebotomist to confirm quality and integrity against the device-based samples. The qualified phlebotomist will attend the participant's home solely for the purpose of collecting the venous blood sample. They are not a member of the research team and will have no role in, or influence over, the participant's self-collection of the capillary blood sample using the study device and accompanying app. The phlebotomist's involvement is limited to venepuncture procedures. C-reactive protein (CRP) concentration will be compared between the two sample types using ELISA assays at PMC from the device sample and gold standard hospital laboratory analysis (Altnagelvin hospital, Western Health and Social Care Trust). This will confirm whether CRP values from home-collected plasma samples via the device are equivalent to standard of care phlebotomy, in terms of sample quality and clinical reliability of CRP levels detected. In addition, participants will be asked post procedure to participate in a one-to-one interview either via Teams, telephone or face to face (either in their own home or in C-TRIC). Interviews will be digitally recorded (following informed consent), transcribed verbatim and analysed following the template analysis style outlined by Miles and Huberman (1994).

Phase 3: Health Economic Analysis We will conduct an initial health economic assessment of BloodTrackR relative to current NHS phlebotomy practice. Metrics will include time saved per patient (reduced travel, waiting, and clinic time), reduction in staff workload compared with current phlebotomy practice, and early cost modelling (device/test vs \~£50 per current phlebotomy episode). These analyses will provide early evidence of workforce and system-level benefits.

03

Conditions studied

  • Rheumatoid Arthritis (RA)
  • Remote Patient Monitoring

Keywords

  • Rheumatoid Arthritis
  • Home Blood Collection
  • Remote Patient Monitoring
  • BloodTrackR
  • Blood Microsampling
  • CRP
  • Usability Study
  • Concordance Study
  • Digital Health
  • Mobile Health
  • Remote Monitoring
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of approximately 20 adults aged 18 years and older with a confirmed diagnosis of rheumatoid arthritis living in or around Derry/Londonderry, Northern Ireland. Participants must be able to understand written and spoken English and have access to WiFi and a smartphone or tablet. Participants will be recruited through rheumatology patient organisations, support groups, community networks, and research recruitment platforms to evaluate the usability, acceptability, and concordance of the BloodTrackR home blood collection platform.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals living with rheumatoid arthritis, who attend community groups or rheumatoid arthritis charity groups
  • Aged 18 years or older
  • Able to understand written and spoken English
  • Individuals who have the capacity to consent
  • Access to WiFi and a smartphone/tablet

Exclusion criteria

Exclusion Criteria:

  • Participants \<18years
  • Participants taking antibiotics/antivirals
  • No access to WiFi or a smartphone/tablet
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Adults with Rheumatoid Arthritis

    Adults aged 18 years and older with rheumatoid arthritis who will use the BloodTrackR home blood collection device and companion mobile application. Participants will collect a blood sample at home and undergo paired venous blood sampling for concordance testing. Usability, acceptability, and user experience will be assessed through questionnaires and interviews.

    Device: BloodTrackR - Home Blood Collection Platform

Interventions

  • DeviceBloodTrackR - Home Blood Collection Platform

    A home-based blood collection device and mobile application that enables remote blood sampling, symptom tracking, temperature monitoring, and sample traceability.

06

What researchers measure

Primary outcomes

  1. Questionnaire to assess usability of the BloodTrackR Home Blood Collection Platform

    Usability of the BloodTrackR device and companion mobile application will be assessed using a study-specific usability questionnaire completed after device use. Participants will indicate whether each step of the blood collection procedure was successfully completed, completed with issues, or not completed, and will provide an overall usability rating on a scale of 0 to 10. Higher scores indicate greater usability and user satisfaction.

    Time frame: Immediately after completion of BloodTrackR device use (same day)

Secondary outcomes

  1. Post-Procedure Semi-Structured Interview on BloodTrackR User Experience

    Participant experience of using the BloodTrackR device and companion mobile application will be explored through a post-procedure semi-structured interview. Interview questions will explore ease of use, acceptability, perceived benefits, barriers to use, and suggestions for improvement. The responses will be summarised descriptively across participants.

    Time frame: Following completion of device use (up to 1 month)

  2. Concordance Between BloodTrackR device and Venous CRP Measurements

    Comparison of C-reactive protein (CRP) concentrations obtained from blood samples collected using BloodTrackR and paired venous blood samples analysed using standard laboratory methods.

    Time frame: 1 week following device use

  3. Successful Home Blood Sample Collection Rate

    Proportion of participants able to successfully collect and return a blood sample using the BloodTrackR device without assistance.

    Time frame: Up to 1 day following device use

  4. Estimated Patient Time Associated With Blood Collection

    A preliminary health economic assessment will compare BloodTrackR with standard NHS phlebotomy pathways. Estimated patient time associated with blood collection, including travel, waiting, and clinic time, comparing BloodTrackR with standard NHS phlebotomy pathways. Findings will be used to inform future economic evaluations of BloodTrackR.

    Time frame: At completion of study participation (up to 3 months)

  5. Estimated Healthcare Staff Workload Associated With Blood Collection

    A preliminary health economic assessment will compare BloodTrackR with standard NHS phlebotomy pathways. Estimated healthcare staff workload associated with blood collection procedures comparing BloodTrackR with standard NHS phlebotomy pathways. Findings will be used to inform future economic evaluations of BloodTrackR.

    Time frame: At completion of study participation (up to 3 months)

  6. Estimated Blood Collection Cost per Participant

    A preliminary health economic assessment will compare BloodTrackR with standard NHS phlebotomy pathways. Estimated cost per participant for blood collection using BloodTrackR compared with standard NHS phlebotomy pathways. Findings will be used to inform future economic evaluations of BloodTrackR.

    Time frame: At completion of study participation (up to 3 months)

07

Study locations

1 of 1 sites recruiting
  • Personalised Medicine Centre
    Londonderry, BT47 6SB, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Sep 2026, 3 months later.

Of 235 non-industry observational studies under Arthritis, Rheumatoid, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 122. This study's planned 3 months is below that.

Counting every sponsor, half of 390 studies reached it within 50 months; a quarter within 25 and three quarters within 113.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2026
First posted
Jun 22, 2026
StartEst.
Jun 2026
Primary completionEst.
Sep 2026
CompletionEst.
Dec 2026
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07660029
Lead sponsor
University of Ulster
Collaborators
National Institute for Health Research, United Kingdom
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Jun 2026 (estimated)
Primary completion
Sep 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 24, 2026

Study contacts

Jency Rajan
Contact
j.rajan@ulster.ac.uk
00447486455613
David Gibson
Contact
d.gibson@ulster.ac.uk
+442871675663
David Gibson
principal investigator · Ulster University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion